Revenue surged 77% to $148.9 million and operating income rose 151% to $49.1 million year-over-year, driven by new and exclusive product launches and strong growth across product lines.Original document: Elite Pharmaceuticals, Inc. [ELTP] SEC 8-K Current Report — Jun. 30 2026This is an AI-generated…
Revenue surged 77% to $148.9 million and operating income rose 151% to $49.1 million year-over-year, driven by new and exclusive product launches and strong growth across product lines.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.